QDEL

21.33

-3.27%↓

NERV

4.06

+7.12%↑

LSTA.US

2.12

+6.53%↑

QDEL

21.33

-3.27%↓

NERV

4.06

+7.12%↑

LSTA.US

2.12

+6.53%↑

QDEL

21.33

-3.27%↓

NERV

4.06

+7.12%↑

LSTA.US

2.12

+6.53%↑

QDEL

21.33

-3.27%↓

NERV

4.06

+7.12%↑

LSTA.US

2.12

+6.53%↑

QDEL

21.33

-3.27%↓

NERV

4.06

+7.12%↑

LSTA.US

2.12

+6.53%↑

Home・Elenco Azioni・Pharming Group NV

P
Pharming Group NV

Chiusa

1.453 -2.02

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.41

Massimo

1.483

Metriche Chiave
By Trading Economics
Entrata	2.9M 7.5M
Vendite	4.1M 97M
EPS	0.006
Margine di Profitto	7.758
Dipendenti	404

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	379M 997M
Apertura precedente	3.47
Chiusura precedente	1.453

Pharming Group NV Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 nov 2025, 17:45 UTC

Utili

I principali Market Mover

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14 nov 2025, 17:31 UTC

Utili

I principali Market Mover

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

14 nov 2025, 16:15 UTC

I principali Market Mover

Scholar Rock Shares Rise on Renewed Apitegromab Hopes

14 nov 2025, 23:56 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14 nov 2025, 23:02 UTC

Discorsi di Mercato

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14 nov 2025, 22:35 UTC

Utili

Acquisizioni, Fusioni, Takeovers

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14 nov 2025, 22:32 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14 nov 2025, 22:29 UTC

Utili

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14 nov 2025, 22:00 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14 nov 2025, 21:50 UTC

Discorsi di Mercato

Utili

Tech, Media & Telecom Roundup: Market Talk

14 nov 2025, 21:18 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14 nov 2025, 20:27 UTC

Discorsi di Mercato

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14 nov 2025, 20:23 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14 nov 2025, 20:17 UTC

Acquisizioni, Fusioni, Takeovers

Several State Attorneys General Oppose Railroad Merger -- WSJ

14 nov 2025, 19:29 UTC

Discorsi di Mercato

Utili

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14 nov 2025, 18:44 UTC

Discorsi di Mercato

Utili

Disney's Growth Now Hinges More on ESPN -- Market Talk

14 nov 2025, 18:27 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

14 nov 2025, 18:27 UTC

Discorsi di Mercato

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14 nov 2025, 18:20 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14 nov 2025, 17:20 UTC

Discorsi di Mercato

Utili

Auto & Transport Roundup: Market Talk

14 nov 2025, 17:20 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Health Care Roundup: Market Talk

14 nov 2025, 17:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

14 nov 2025, 16:51 UTC

Discorsi di Mercato

Starbucks Gets Holiday Sales Lift -- Market Talk

14 nov 2025, 16:48 UTC

Discorsi di Mercato

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

14 nov 2025, 16:38 UTC

Discorsi di Mercato

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

14 nov 2025, 16:30 UTC

Acquisizioni, Fusioni, Takeovers

Merck Is Paying Up for Flu Biotech as M&A Spree Continues -- Barrons.com

14 nov 2025, 16:28 UTC

Discorsi di Mercato

Ukraine Strike on Russian Port Lifts Distillates -- Market Talk

14 nov 2025, 15:59 UTC

Discorsi di Mercato

U.S. Natural Gas Inventories Rise More Than Expected -- Market Talk

14 nov 2025, 15:06 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

14 nov 2025, 15:06 UTC

Discorsi di Mercato

Dollar Could Benefit From U.K., French Fiscal Concerns -- Market Talk

Confronto tra pari

Modifica del prezzo

Pharming Group NV Previsione

Consenso sulla valutazione

By TipRanks

0 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 0 che hanno fornito valutazioni azionarie a Pharming Group NV - Dist negli ultimi 3 mesi.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.